TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are between ages 18-65 years old.~* Meet DSM-IV criteria for nicotine dependence.~* Smoke at least 15 cigarettes (3/4 pack) daily (averaged over 1 week, in the past 1 month) and have an expired breath CO level \> 10.~* At the time of initial evaluation, are motivated to quit smoking in the next 30 days.~* Receive a score of ≥ 10 on the Insomnia Severity Index (ISI)~* Have the capacity to give informed consent, and are English-speaking.~Exclusion Criteria:~* Are taking an over-the-counter or prescription medications that are known to affect sleep.~* Are taking medications contraindicated for use with eszopiclone or bupropion including: Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Nefazodone, Troleandomycin, Ritonavir, Nelfinavir, Trazodone, and Methadone.~* Are using any over-the-counter analgesics that contain caffeine.~* Have serious medical disorders that may make participation in the trial unsafe.~* Are physiologically dependent on and/or abusing alcohol or other drugs of abuse (e.g., cocaine, opiates, benzodiazepines, etc.) in the past 6 months prior to randomization into the trial.~* Consume greater than 1 alcoholic beverage per day or greater than 7 alcoholic drinks per week.~* Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic disorder or post-traumatic stress disorder, or a current or past history bipolar disorder, schizophrenia, or anorexia or bulimia nervosa. Have a past history of major depression, with historical evidence of suicidal or homicidal behavior, or psychotic symptoms.~* Have the presence of suicidal or homicidal ideation, or significant impairment of social or occupational functioning, either at study baseline during the evaluation process, or during participation in the trial.~* Are from the same household as another study participant.~* A history of seizures of any etiology.~* A history of hypersensitivity to bupropion or Lunesta (eszopiclone).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Zyban + Lunesta (Type: EXPERIMENTAL): Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
- Zyban + Placebo (Type: PLACEBO_COMPARATOR): Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radial Forearm Versus the Ulnar Forearm Free Flap

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with planned forearm free flap reconstruction~* Patients who are deemed equal surgical candidates for radial forearm free flap and ulnar forearm free flap reconstruction~* Preoperative Allen's test completed and passed~* Patients have the capacity to complete the informed consent process~Exclusion Criteria:~* Patients that are not candidates for a forearm flap based on their physiology~* Clinically evident peripheral neuropathy (e.g., diabetic neuropathy, leprosy)~* Patients requiring concurrent forearm bone for reconstruction~* Child, prisoner, or other vulnerable group

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Radial forearm free flap (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive a radial forearm free flap.
- Ulnar forearm free flap (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive an ulnar forearm free flap.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperoxia and Microvascular Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Coronary angiography done in the context of suspicion of coronary artery disease (CAD)~Exclusion Criteria:~* Respiratory failure requiring intubation or supplementary oxygen~* Severe chronic obstructive pulmonary disease~* Significant arrhythmia precluding waveform analysis (e.g., excessive premature ventricular contractions or atrial fibrillation)~* Severe valvular heart disease,~* Suspected elevated central venous pressure (CVP)~* Heart failure as defined by New York Heart Association class III or IV~* Previous coronary revascularization or heart transplantation~* Severe hypertension (systolic pressure \>200 mmHg and diastolic pressure \>120 mmHg at rest)~* Contraindications to adenosine infusion~* Contraindication to acetylcholine (Ach) infusion~* Severe bronchial asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Hyperoxia (Type: EXPERIMENTAL): * assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~* assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests
- Normoxia (Type: PLACEBO_COMPARATOR): * assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~* assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with paroxysmal atrial fibrillation (AF) (recent or new onset) or subjects with persistent AF at the time of randomization~* Subjects who are hemodynamically stable~* Subjects with a low risk of thromboembolic potential~* Subjects who are willing to comply with the reproductive precautions~Exclusion Criteria:~Subjects with:~* History of long QT syndrome, Torsade de Pointes or an uncorrected QT interval of \> 450 ms~* History of myocardial infarction within 6 months of screening~* Acute coronary syndrome, angina or active myocardial ischemia diagnosed by ECG, or other imaging within 6 months of screening~* History of ventricular tachycardia, fibrillation, or resuscitated cardiac arrest~* History of clinically significant congenital heart disease~* Presence of severe aortic or mitral stenosis, aortic or mitral regurgitation, atrial septal defect, or other conditions leading to AF~* Diagnosis of heart failure NYHA Class II-IV or with an ejection fraction \<40% (Part 1 only)~* Diagnosis of heart failure NYHA Class IV or NYHA I, II, or III with an ejection fraction \<35% (Part 2 only)~* Concomitant treatment with class I or III anti-arrhythmics agents unless the medication was discontinued more than 5 half-lives before dosing~* History of seizures~* Diagnosis of atrial flutter~* Diagnosis of stroke, TIA (transient ischemic attack), or any transient neurological deficit within 1 year of screening or known carotid artery stenosis of \>50%~* Cardiac surgery within 3 months of screening~* Bradycardia (\< 50 bpm) or sick sinus syndrome, unless controlled by a pacemaker~* Current reversible cause of AF~* Wolff-Parkinson-White syndrome~* Any congenital abnormality, severe valve disease~* Subjects who have taken another investigational product within 30 days of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Persistent or Paroxysmal AF Part 1: OPC-108459 (Type: EXPERIMENTAL): To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
- Persistent or Paroxysmal AF Part 1: Placebo (Type: PLACEBO_COMPARATOR): None
- Persistent or Paroxysmal AF Part 2: OPC-108459 (Type: EXPERIMENTAL): Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
- Placebo Part 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Prediction of Postoperative Physical Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for primary unilateral TKA surgery~* TKA surgery due to end-stage OA of the knee~* Able to perform the preoperative assessment 4 weeks before surgery~* Able to fulfill the KOOS by phone 6 weeks postoperatively~* Mastery of the Dutch language~Exclusion Criteria:~* Undergoing revision arthroplasty, bilateral TKA or hemi-arthroplasty surgery~* TKA not due to KOA~* Patients who weren't able to perform the preoperative assessment or to fulfill the KOOS postoperatively~* Cognitive impairments~* Complete dependence on a wheelchair~* Unable to sign the informed consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients awaiting TKA (Type: None): Patients awaiting unilateral total knee arthroplasty due to end-stage knee osteoarthritis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria for amyloid subjects:~* Age \> 18 years~* Biopsy proven amyloidosis outside the heart with typical echocardiographic appearance of cardiac involvement, or a positive cardiac biopsy.~* Diagnosis of AL amyloidosis by standard criteria (evidence of plasma cell dyscrasia with appropriate tissue staining for AL) OR~* Diagnosis of TTR amyloidosis (no evidence of plasma call dyscrasia and positive TTR staining of amyloid in tissue biopsy)~* Able and willing to provide informed consent to participate in the study procedures~Exclusion Criteria:~* Pregnancy~* Serious non-cardiac medical illness which will preclude research study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- F-18 florbetapir PET-Amyloid Subjects (Type: EXPERIMENTAL): Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
- F-18 florbetapir PET-Healthy Controls (Type: OTHER): Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
- F-18 florbetapir PET-Amyloid Reproducibility Subjects (Type: EXPERIMENTAL): Some of the individuals with documented cardiac amyloidosis from arm 1 will undergo a second F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) within 30 days to measure reproducibility

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: VALIDITY AND RELIABILITY OF THE 6-MINUTES WALKING TEST EVALUATED BY FEETME® INSOLES

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Being between 18 and 80 years old~  * Able to use a laptop~ * Able to walk 100 meters without any aid~ * Accustomed to using a smartphone~Exclusion Criteria:~* Surgery with the possibility of impacting gait in the previous 3 months having had an impact on gait: orthopedic surgery, trauma of the lower limbs and spine, gynecological or urological surgery, brain and spinal cord surgery • Chronic disease affecting walking: Rheumatological, orthopedic, painful, neurological pathology.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Healthy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia~* Measurable disease~* Slowly progressing disease not requiring therapy for at least 3-6 months and who do not meet consensus panel criteria for initiation of therapy~* ECOG Performance status of 0 or 1~* Adequate organ function as defined in the protocol~* Patients should agree to avoid grapefruit juice which is a major inhibitor of CYP 3A4~Exclusion Criteria:~* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than four weeks earlier~* Patients who have had rituximab within 3 months prior to entering the study~* Patients who have taken any Statin in the past~* Patients who take cyclosporin, danazol, or gemfibrozil will be excluded~* Prior history of rhabdomyolysis~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements~* Pregnant or breastfeeding women~* HIV-positive~* Patients who take verapamil will be excluded~* Patients with active or history of liver disease~* Patients who consume more than three alcoholic beverages per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects from 45 to 85 years of age~* Definite IPF within 3 years prior to screening~* Be able to walk at least 50 meters~Key Exclusion Criteria:~* Significant diseases other than IPF~* Obstructive lung disease~* Aortic aneurysm greater than or equal to 3.5 cm in diameter~* Treatment with immunosuppressive, cytotoxic, or antifibrotic drugs \< 28 days prior to randomization are not permitted.~  * N-acetylcysteine is permitted provided the individual has been on a stable dose for \> 4 weeks prior to screening~ * Concomitant use of pirfenidone or nintedanib must be in accordance with the approved prescribing instructions in the country where the site is located~* Individuals actively listed for lung transplant are excluded. However individuals at transplant centers with long waiting times (greater than 1 year) may be permitted to enter the study after discussion with Medical Monitor.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Simtuzumab (Type: EXPERIMENTAL): Participants will receive simtuzumab for up to 254 weeks.
- Simtuzumab Placebo (Type: PLACEBO_COMPARATOR): Participants will receive simtuzumab placebo for up to 254 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ethanol Locks for the Treatment of Central Venous Line Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 6 months-23 years~* documented central line infection with bacteria or fungus (positive blood culture)~Exclusion Criteria:~* allergy or intolerance to ethanol~* pregnant or breastfeeding~* central line tunnel or exit site infection

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
- 2 (Type: PLACEBO_COMPARATOR): heparin flush 10 units/ml lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. heparin flush solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective of Children With ADHD and Cardiac Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ADHD~* myocardial ischemia/infarct~* no previous cardiac history~* added Straterra~* already taking Adderall~Exclusion Criteria:~* those who do not meet inclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Debritom - Micro Water Jet Technology and Wound Healing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18 or older~* The ability and willingness to provide Informed consent~* Presence of a chronic lower extremity ulcer~* Chronic ulcer is defined as that greater than 4 weeks in duration.~* Subject's informed consent for participation prior to proceeding with micro water jet technology debridement~* Patient's ulcer cannot exhibit any gross clinical signs of infection.~* Patient is willing to participate in all procedures and follow up evaluations necessary to complete the study.~* Patient willing and able to comply with having micro water jet technology debridement potentially weekly or biweekly as part of their wound care treatment plan for up to 20 weeks.~Exclusion Criteria:~* Patients with active wound infection, or untreated osteomyelitis~* Patients with dementia, or impaired cognitive function~* Patients who are unable or unwilling to participate in all procedures and follow up evaluations~* Patient has Active Charcot foot~* Patient with malignant wounds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Micro Water Jet Technology (Debritom) (Type: OTHER): Debritom is a hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.~All subject will get the Debritom.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of the Robotic Uterine Manipulator

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female participant must be scheduled for a total laparoscopic or robotic-assisted hysterectomy for a gynecologic condition~* Female participants must be 18 years of age or older~Exclusion Criteria:~* Female participant is not eligible if the surgeon does not plan to use a uterine manipulator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- total laparoscopic or robotic-assisted hysterectomy (Type: EXPERIMENTAL): All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues